Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.

Public rows: 8,404
Generated: 2026-09-12
Schema version: 1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups: 8,404
Source sentence records: 20,358
Asserted sentences: 4,700
Denied sentences: 7,494
Polarity not recorded: 8,164
Medicines represented: 755
Counterparties represented: 36
Corpus records considered: 9,855; All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups: 617
inhibitor groups: 3,131
not_recorded groups: 3,074
substrate groups: 1,582

Method

How the rows were made

A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b

In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b

Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b

Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

Field	Type	Meaning
medicineSlug	string	Stable RNAWiki medicine route key.
medicineName	string	Recorded medicine name; not normalized for display style.
counterparty	string	The exact recorded counterparty spelling.
role	string	SUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCount	number	Sentence records whose polarity is ASSERTED.
deniedCount	number	Sentence records whose polarity is NEGATED.
polarityNotRecordedCount	number	Sentence records for which the parser did not settle assertion or denial.
sentences	sentence[]	Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Showing 3,351–3,360 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

Projected row 3351
Medicine slug
gabapentin-enacarbil
Medicine name
Gabapentin Enacarbil
Enzyme or transporter
P-GLYCOPROTEIN
Role
NOT_RECORDED
Asserted sentences
0
Denied sentences
0
Polarity not recorded
2
Complete sentence records
1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:4c486fc7-c8c4-4c6c-b30c-366dabaeaadd (opens source in a new tab)
  Gabapentin Enacarbil label
  Version not recorded · Effective date not recorded
  Gabapentin enacarbil is neither a substrate nor an inhibitor of P-glycoprotein in vitro .
2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:4c486fc7-c8c4-4c6c-b30c-366dabaeaadd (opens source in a new tab)
  Gabapentin Enacarbil label
  Version not recorded · Effective date not recorded
  Gabapentin enacarbil is neither a substrate nor an inhibitor of P-glycoprotein in vitro .
Projected row 3352
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP1A2
Role
INHIBITOR
Asserted sentences
0
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
Projected row 3353
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP2A6
Role
INHIBITOR
Asserted sentences
0
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
Projected row 3354
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP2D6
Role
INHIBITOR
Asserted sentences
6
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  In vitro studies indicate that cytochrome CYP2D6 and CYP3A4 were the major cytochrome P450 isoenzymes involved in the metabolism of galantamine, and inhibitors of both pathways increase oral bioavailability of galantamine modestly.
2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Other Drugs on Galantamine: • CYP3A4 Inhibitors : Ketoconazole : Ketoconazole, a strong inhibitor of CYP3A4 and an inhibitor of CYP2D6, when administered at a dose of 200 mg two times a day for 4 days, increased the AUC of galantamine by 30%.
3. ASSERTEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Paroxetine : Paroxetine, a strong inhibitor of CYP2D6, when administered at a dose of 20 mg/day for 16 days, increased the oral bioavailability of galantamine by about 40%. • H2 Antagonists : Galantamine was administered as a single dose of 4 mg on Day 2 of a 3-day treatment with either cimetidine (800 mg daily) or ranitidine (300 mg daily).
4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  In vitro studies indicate that cytochrome CYP2D6 and CYP3A4 were the major cytochrome P450 isoenzymes involved in the metabolism of galantamine, and inhibitors of both pathways increase oral bioavailability of galantamine modestly.
5. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Other Drugs on Galantamine: • CYP3A4 Inhibitors : Ketoconazole : Ketoconazole, a strong inhibitor of CYP3A4 and an inhibitor of CYP2D6, when administered at a dose of 200 mg two times a day for 4 days, increased the AUC of galantamine by 30%.
6. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Paroxetine : Paroxetine, a strong inhibitor of CYP2D6, when administered at a dose of 20 mg/day for 16 days, increased the oral bioavailability of galantamine by about 40%. • H2 Antagonists : Galantamine was administered as a single dose of 4 mg on Day 2 of a 3-day treatment with either cimetidine (800 mg daily) or ranitidine (300 mg daily).
7. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
8. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
Projected row 3355
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP2D6
Role
NOT_RECORDED
Asserted sentences
0
Denied sentences
0
Polarity not recorded
14
Complete sentence records
1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  O-demethylation, mediated by CYP2D6 was greater in extensive metabolizers of CYP2D6 than in poor metabolizers.
2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  In studies of oral 3 H-galantamine, unchanged galantamine and its glucuronide, accounted for most plasma radioactivity in poor and extensive CYP2D6 metabolizers.
3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  CYP2D6 Poor Metabolizers : Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of CYP2D6 isozyme.
4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  After a single oral dose of 4 mg or 8 mg galantamine, CYP2D6 poor metabolizers demonstrated a similar C max and about 35% AUC ∞ increase of unchanged galantamine compared to extensive metabolizers.
5. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  A total of 356 patients with Alzheimer’s disease enrolled in two Phase 3 studies were genotyped with respect to CYP2D6 (n=210 hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers).
6. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Based on in vitro studies, CYP2D6 and CYP3A4 were the major enzymes involved in the metabolism of galantamine.
7. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  CYP2D6 was involved in the formation of O-desmethyl-galantamine, whereas CYP3A4 mediated the formation of galantamine-N-oxide.
8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  O-demethylation, mediated by CYP2D6 was greater in extensive metabolizers of CYP2D6 than in poor metabolizers.
9. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  In studies of oral 3 H-galantamine, unchanged galantamine and its glucuronide, accounted for most plasma radioactivity in poor and extensive CYP2D6 metabolizers.
10. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  CYP2D6 Poor Metabolizers : Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of CYP2D6 isozyme.
11. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  After a single oral dose of 4 mg or 8 mg galantamine, CYP2D6 poor metabolizers demonstrated a similar C max and about 35% AUC ∞ increase of unchanged galantamine compared to extensive metabolizers.
12. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  A total of 356 patients with Alzheimer’s disease enrolled in two Phase 3 studies were genotyped with respect to CYP2D6 (n=210 hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers).
13. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Based on in vitro studies, CYP2D6 and CYP3A4 were the major enzymes involved in the metabolism of galantamine.
14. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  CYP2D6 was involved in the formation of O-desmethyl-galantamine, whereas CYP3A4 mediated the formation of galantamine-N-oxide.
Projected row 3356
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP2E1
Role
INHIBITOR
Asserted sentences
0
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
Projected row 3357
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP3A4
Role
INHIBITOR
Asserted sentences
4
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  In vitro studies indicate that cytochrome CYP2D6 and CYP3A4 were the major cytochrome P450 isoenzymes involved in the metabolism of galantamine, and inhibitors of both pathways increase oral bioavailability of galantamine modestly.
2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Other Drugs on Galantamine: • CYP3A4 Inhibitors : Ketoconazole : Ketoconazole, a strong inhibitor of CYP3A4 and an inhibitor of CYP2D6, when administered at a dose of 200 mg two times a day for 4 days, increased the AUC of galantamine by 30%.
3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  In vitro studies indicate that cytochrome CYP2D6 and CYP3A4 were the major cytochrome P450 isoenzymes involved in the metabolism of galantamine, and inhibitors of both pathways increase oral bioavailability of galantamine modestly.
4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Other Drugs on Galantamine: • CYP3A4 Inhibitors : Ketoconazole : Ketoconazole, a strong inhibitor of CYP3A4 and an inhibitor of CYP2D6, when administered at a dose of 200 mg two times a day for 4 days, increased the AUC of galantamine by 30%.
5. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
6. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Effect of Galantamine on Other Drugs: • In Vitro Studies : In vitro studies show that galantamine did not inhibit the metabolic pathways catalyzed by CYP1A2, CYP2A6, CYP3A4, CYP4A, CYP2C, CYP2D6 or CYP2E1.
Projected row 3358
Medicine slug
galantamine
Medicine name
Galantamine
Enzyme or transporter
CYP3A4
Role
NOT_RECORDED
Asserted sentences
0
Denied sentences
0
Polarity not recorded
4
Complete sentence records
1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Based on in vitro studies, CYP2D6 and CYP3A4 were the major enzymes involved in the metabolism of galantamine.
2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  CYP2D6 was involved in the formation of O-desmethyl-galantamine, whereas CYP3A4 mediated the formation of galantamine-N-oxide.
3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  Based on in vitro studies, CYP2D6 and CYP3A4 were the major enzymes involved in the metabolism of galantamine.
4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d5b0e225-e94d-4324-afb2-b6e51c949dd0 (opens source in a new tab)
  Galantamine label
  Version not recorded · Effective date not recorded
  CYP2D6 was involved in the formation of O-desmethyl-galantamine, whereas CYP3A4 mediated the formation of galantamine-N-oxide.
Projected row 3359
Medicine slug
ganaxolone
Medicine name
Ganaxolone
Enzyme or transporter
BCRP
Role
INHIBITOR
Asserted sentences
0
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d91612c4-b03a-4be4-a1ee-6a13e3b83d4e (opens source in a new tab)
  Ganaxolone label
  Version not recorded · Effective date not recorded
  Ganaxolone does not inhibit BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or BSEP at clinically relevant concentrations.
2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d91612c4-b03a-4be4-a1ee-6a13e3b83d4e (opens source in a new tab)
  Ganaxolone label
  Version not recorded · Effective date not recorded
  Ganaxolone does not inhibit BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or BSEP at clinically relevant concentrations.
Projected row 3360
Medicine slug
ganaxolone
Medicine name
Ganaxolone
Enzyme or transporter
BCRP
Role
SUBSTRATE
Asserted sentences
0
Denied sentences
2
Polarity not recorded
0
Complete sentence records
1. NEGATEDpharmacokineticsRetrieved 2026-08-30
  FDA_LABEL:d91612c4-b03a-4be4-a1ee-6a13e3b83d4e (opens source in a new tab)
  Ganaxolone label
  Version not recorded · Effective date not recorded
  Transporter Systems Ganaxolone is not a substrate of BCRP, P-gp, OCT1, OCT2, OATP1B1, or OATP1B3 at clinically relevant concentrations.
2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
  FDA_LABEL:d91612c4-b03a-4be4-a1ee-6a13e3b83d4e (opens source in a new tab)
  Ganaxolone label
  Version not recorded · Effective date not recorded
  Transporter Systems Ganaxolone is not a substrate of BCRP, P-gp, OCT1, OCT2, OATP1B1, or OATP1B3 at clinically relevant concentrations.

Access

Query or download the projection

View this filtered page as JSON Download up to 200 filtered CSV rows

GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=3350

Allowed query parameters

q: Case-insensitive text search over the public fields named for this dataset.
role: Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty: Exact recorded counterparty spelling.
limit / offset: Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy